News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
203,258 Results
Type
Article (19666)
Company Profile (111)
Press Release (183473)
Multimedia
Podcasts (33)
Webinars (14)
Section
Business (63608)
Career Advice (825)
Deals (8974)
Drug Delivery (74)
Drug Development (18657)
Employer Resources (143)
FDA (3338)
Job Trends (6044)
News (94869)
Policy (7060)
Tag
Academia (1496)
Academic (2)
Accelerated approval (2)
Adcomms (16)
Allergies (25)
Alliances (17371)
ALS (42)
Alzheimer's disease (631)
Antibody-drug conjugate (ADC) (83)
Approvals (3403)
Artificial intelligence (198)
Autoimmune disease (29)
Automation (17)
Bankruptcy (51)
Best Places to Work (4883)
BIOSECURE Act (12)
Biosimilars (61)
Biotechnology (60)
Bladder cancer (38)
Brain cancer (14)
Breast cancer (153)
Cancer (1098)
Cardiovascular disease (121)
Career advice (744)
Career pathing (34)
CAR-T (80)
CDC (17)
Cell therapy (208)
Cervical cancer (9)
Clinical research (14803)
Collaboration (593)
Compensation (135)
Complete response letters (10)
COVID-19 (998)
CRISPR (41)
C-suite (330)
Cystic fibrosis (50)
Data (1432)
Decentralized trials (1)
Denatured (22)
Depression (38)
Diabetes (113)
Diagnostics (2425)
Digital health (11)
Diversity (10)
Diversity, equity & inclusion (37)
Drug discovery (86)
Drug pricing (53)
Drug shortages (4)
Duchenne muscular dystrophy (60)
Earnings (15143)
Editorial (19)
Employer branding (23)
Employer resources (122)
Events (30524)
Executive appointments (535)
FDA (4033)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (1)
Frontotemporal dementia (5)
Funding (569)
Gene editing (67)
Generative AI (22)
Gene therapy (151)
GLP-1 (327)
Government (1375)
Guidances (115)
Healthcare (4931)
HIV (22)
Huntington's disease (20)
IgA nephropathy (19)
Immunology and inflammation (46)
Immuno-oncology (1)
Indications (9)
Infectious disease (1085)
Inflammatory bowel disease (71)
Inflation Reduction Act (8)
Influenza (32)
Intellectual property (51)
Interviews (118)
IPO (3634)
IRA (17)
Job creations (1308)
Job search strategy (638)
Kidney cancer (2)
Labor market (71)
Layoffs (190)
Leadership (18)
Legal (1182)
Liver cancer (25)
Longevity (8)
Lung cancer (149)
Lymphoma (106)
Machine learning (11)
Management (43)
Manufacturing (235)
MASH (25)
Medical device (2645)
Medtech (2653)
Mergers & acquisitions (5686)
Metabolic disorders (286)
Multiple sclerosis (60)
NASH (9)
Neurodegenerative disease (73)
Neuropsychiatric disorders (11)
Neuroscience (982)
NextGen: Class of 2025 (2081)
Non-profit (1678)
Now hiring (58)
Obesity (148)
Opinion (110)
Ovarian cancer (33)
Pain (55)
Pancreatic cancer (35)
Parkinson's disease (64)
Partnered (18)
Patents (84)
Patient recruitment (75)
Peanut (15)
People (27646)
Pharmaceutical (26)
Pharmacy benefit managers (2)
Phase I (4345)
Phase II (6109)
Phase III (5875)
Pipeline (802)
Policy (88)
Postmarket research (556)
Preclinical (2495)
Press Release (61)
Prostate cancer (52)
Psychedelics (25)
Radiopharmaceuticals (63)
Rare diseases (190)
Real estate (2538)
Recruiting (58)
Regulatory (5428)
Reports (37)
Research institute (1279)
Resumes & cover letters (108)
Rett syndrome (2)
RNA editing (6)
RSV (38)
Schizophrenia (49)
Series A (106)
Series B (66)
Service/supplier (8)
Sickle cell disease (28)
Special edition (9)
Spinal muscular atrophy (52)
Sponsored (16)
Startups (2011)
State (1)
Stomach cancer (6)
Supply chain (31)
Tariffs (13)
The Weekly (11)
Vaccines (284)
Venture capital (46)
Weight loss (97)
Women's health (22)
Worklife (17)
Date
Today (48)
Last 7 days (236)
Last 30 days (912)
Last 365 days (9654)
2025 (8117)
2024 (11391)
2023 (12949)
2022 (15520)
2021 (17634)
2020 (16239)
2019 (14947)
2018 (10794)
2017 (10275)
2016 (10148)
2015 (10839)
2014 (7987)
2013 (6913)
2012 (7343)
2011 (7527)
2010 (7015)
Location
Africa (327)
Alabama (26)
Alaska (4)
Arizona (79)
Arkansas (4)
Asia (11462)
Australia (2001)
California (2704)
Canada (911)
China (237)
Colorado (140)
Connecticut (90)
Delaware (142)
Europe (29809)
Florida (411)
Georgia (79)
Hawaii (2)
Idaho (11)
Illinois (182)
India (30)
Indiana (226)
Iowa (11)
Japan (126)
Kansas (37)
Kentucky (11)
Louisiana (4)
Maine (7)
Maryland (281)
Massachusetts (2260)
Michigan (115)
Minnesota (146)
Mississippi (3)
Missouri (43)
Montana (5)
Nebraska (9)
Nevada (20)
New Hampshire (16)
New Jersey (838)
New Mexico (16)
New York (958)
North Carolina (456)
North Dakota (9)
Northern California (1331)
Ohio (89)
Oklahoma (9)
Oregon (18)
Pennsylvania (456)
Puerto Rico (5)
Rhode Island (14)
South America (390)
South Carolina (6)
Southern California (921)
Tennessee (48)
Texas (364)
United States (10362)
Utah (60)
Virginia (67)
Washington D.C. (28)
Washington State (223)
West Virginia (1)
Wisconsin (55)
203,258 Results for "dermavant sciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Dermavant Announces Approval of Tapinarof in both Psoriasis and Atopic Dermatitis in Japan
Dermavant Sciences has received approval in Japan for tapinarof cream, 1% for the treatment of both adults with psoriasis and patients 12 years of age and older with atopic dermatitis.
June 25, 2024
·
5 min read
M&A
Roivant Deals Again, Sending Dermavant to Organon in Sale Worth Up to $1.2B
The sale of Dermavant clears the way for Roivant to focus on autoimmune-focused Immunovant and a slate of upcoming pivotal trials.
September 18, 2024
·
3 min read
·
Annalee Armstrong
Business
Dermavant Champions a Culture that Earns Three Best Workplace Rankings in 2023 by Fortune and Great Place to Work®
Dermavant Sciences announced that the company has been named one of 2023’s Best Workplaces for Millennials™, Best Medium Workplaces™ and Best Workplaces in BioPharma™ by Fortune magazine and Great Place to Work® — Dermavant’s eighth recognition by the organizations.
October 13, 2023
·
6 min read
Business
Dermavant Appoints John Darden as New Head of Marketing
Dermavant Sciences today announced the appointment of John Darden as Vice President of Marketing. Darden brings more than 15 years of sales, marketing and market access experience in dermatology and immunology.
October 5, 2023
·
3 min read
Biotech Beach
Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Dermavant Sciences today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children 2 years of age and older.
April 29, 2024
·
5 min read
Drug Development
Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD
Dermavant Sciences today announced that the data from ADORING 1 and ADORING 2, two identical, double-blind, randomized, vehicle-controlled pivotal Phase 3 trials of VTAMA® (tapinarof) cream, 1% for adults and children 2 years of age and older with atopic dermatitis (AD) has been published in the Journal of the American Academy of Dermatology.
May 21, 2024
·
8 min read
Biotech Beach
Dermavant Submits Supplemental New Drug Application (sNDA) to FDA for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced that it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for VTAMA® (tapinarof) cream.
February 14, 2024
·
7 min read
Drug Development
Dermavant Announces Positive Data from the ADORING Phase 3 Development Program in Atopic Dermatitis with VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced new positive efficacy and safety data from analyses of the company’s ADORING Phase 3 development program in atopic dermatitis.
January 11, 2024
·
10 min read
Job Trends
Report: U.S. Life Sciences Job Market Report Q3 2025
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
October 16, 2025
·
1 min read
·
BioSpace Insights
Press Releases
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
October 28, 2024
·
11 min read
1 of 20,326
Next
